Updated: Pfizer to buy Seagen for $43B, ending long-running M&A saga for biotech
Pfizer will buy cancer drugmaker Seagen for $43 billion in one of the industry’s biggest deals in years.
The deal, for $229 a share, ends a long-running drama. Pfizer appears to have won by being willing to pay up: In July, Merck was reported to be in talks for a deal at or over $40 billion that fell apart over price. In February, Pfizer was reportedly in talks with Seagen for more than $30 billion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.